Formulation Development Solutions

  1. Human ADME Studies: Human Metabolism Data For Regulatory Submission 10/16/2025

    Integrated human ADME studies streamline the process from 14C synthesis to clinical conduct and final reporting to accelerate your drug development program.

  2. HyClone™ Prime Expression Medium 11/11/2025

    Discover a medium that supports high-density HEK293 growth and robust AAV titers across scales for bioprocessing teams seeking consistency and scalability in viral vector manufacturing.

  3. The Way Forward In Antibody Therapeutics Purification 8/11/2022

    We have developed an innovative portfolio of affinity chromatography resins to support you in the downstream process of next-generation antibody therapeutics.

  4. Gibco Efficient-Pro Medium And Feeds Evaluation Guide 6/9/2025

    Discover a high-performing solution for mAb production designed to significantly improve titers, cell viability, and protein quality in CHO cell lines.

  5. Small Is Powerful, Small Is Green

    As the pharmaceutical industry innovates and evolves, learn more about how Nanoform can play a critical role in empowering your company's journey to net zero.

  6. Method Optimization

    We offer a comprehensive method optimization service to take early stage development methods with poor stability indication, excessive run time lengths, or legacy column chemistries and modify them.

  7. ACQUITY Premier Analytical Solution 6/29/2022

    The ACQUITY Premier Solution enables your lab to make informed decisions and reduce risk with stronger analytical capabilities to detect more of your sample components from the very beginning.

  8. Expediting Drug Discovery From Concept To Commercialization 8/13/2024

    Explore a suite of services designed to accelerate drug discovery and development, from custom reagent production and high-throughput screening to advanced in vitro pharmacology and DMPK assays.

  9. Integrated Programs To Bridge Molecules From Discovery Into Clinical Development 1/4/2023

    A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.

  10. A High-Purity Excipient Suitable For High-Risk Vaccine Applications 7/21/2025

    Examine an ultra-pure, sustainable alternative to shark-derived squalene. With ≥99% purity, it ensures safety, consistency, and ethical sourcing for innovation.